TICKERNERD
Menu
CADLCADLHealthcare · Biotechnology

CADL Stock Forecast: Candel Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$11
−6.93% on the day

The 9 Wall Street analysts covering Candel Therapeutics, Inc. hold a median 12-month price target of $23 — +113.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$806.9M
Ticker Nerd rank
41 / 100
Median analyst target
$23
Analysts covering
9
Revenue$0.0
Operating income−$26.7M
Net income−$38.9M
Free cash flow−$17.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−18.7%
1M
−1.0%
YTD
+86.6%
1Y
+114.5%
From 52W high
−23.3%
From 52W low
+138.6%
$4
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CADL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Candel Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
77
Value
76
Accruals
71
Volatility
65
Quality
64
Size
48
Revisions
28
Growth
22
Issuance
7

Momentum (77): The shares have been drifting up relative to others.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CADL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CADL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26CADLHigh $29Median $23Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
8 Buy1 Hold0 Sell
Low $12Median $23High $29

The green dot is the last close — the median target sits +113.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026B of A SecuritiesMaintainsNeutral$9.00 → $12
13 Aug 2026HC Wainwright & Co.ReiteratesBuy$23
13 July 2026StifelInitiatesBuy$22
13 July 2026StifelInitiatesBuy—
20 Apr 2026Cantor FitzgeraldInitiatesOverweight—
18 Mar 2026CitigroupMaintainsBuy—
13 Mar 2026Canaccord GenuityMaintainsBuy—
13 Mar 2026CitigroupMaintainsBuy—
8 Dec 2025Stephens & Co.ReiteratesOverweight—
21 Nov 2025Freedom BrokerMaintainsBuy—
14 Nov 2025CitigroupMaintainsBuy—
28 Oct 2025Stephens & Co.InitiatesOverweight—
21 Oct 2025LifeSci CapitalInitiatesOutperform—
29 Sept 2025HC Wainwright & Co.ReiteratesBuy—
3 Sept 2025B of A SecuritiesDowngradeNeutral—
30 June 2025HC Wainwright & Co.AssumesBuy$23
11 Apr 2025HC Wainwright & Co.ReiteratesBuy—
14 Mar 2025HC Wainwright & Co.ReiteratesBuy—
26 Feb 2025Canaccord GenuityMaintainsBuy—
26 Feb 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CADL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CADL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Candel Therapeutics, Inc. returned +114.5% against +17.5% for the S&P 500, dividends included.

CADL vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26CADLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CADL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Candel Therapeutics, Inc. (CADL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−14.6×

Cheaper than 95% of US stocks

Price / sales
—
Price / book
6.4×

Cheaper than 16% of US stocks

EV / EBITDA
−9.2×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−81.8%

Higher than 16% of US stocks

Return on assets
−28.6%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Candel Therapeutics, Inc. (CADL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Candel Therapeutics, Inc. has a market value of $806.9M and an enterprise value of $654.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$88.5M.

  • Diluted earnings per share, trailing twelve months: $−1.41.

  • Free cash flow in the twelve months to 30 June 2026: −$57.3M.

  • Shares outstanding: 76.1M.

  • Trailing P/E: −14.6×; forward P/E: −16.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Candel Therapeutics, Inc. employs 55 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

CADL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CADLCandel Therapeutics, Inc.$806.9M
41
ACRSAclaris Therapeutics, Inc.$783.1M
67
NVCTNuvectis Pharma, Inc.$756.3M
67
GYREGyre Therapeutics, Inc.$750.3M
41
ANNXAnnexon, Inc.$746.9M
33
MNPRMonopar Therapeutics, Inc.$736.8M
57
CLYMClimb Bio, Inc.$816.0M
60

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Candel Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CADL news & analysis

Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors

GlobeNewsWire · 10 Sept 2026neutral

Candel Therapeutics announced the appointment of Martine Zimmermann, PharmD, to its Board of Directors, effective September 8, 2026. The company is a clinical-stage biopharmaceutical firm developing immunotherapies for cancer patients.

Why it matters — A CADL watcher would care because the addition of an experienced pharmaceutical executive to the board could bring relevant industry expertise to the company's governance.

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 1 Sept 2026neutral

Candel Therapeutics announced that on August 31, 2026, its Compensation Committee granted stock options to purchase an aggregate of 31,400 shares of common stock at an exercise price of $13.07 per share to two new employees, under Nasdaq Listing Rule 5635(c)(4).

Why it matters — The inducement stock-option grants signal the company is bringing on new talent, which CADL watchers may track as part of the company's ongoing operations.

Candel Therapeutics to Present at September Investor Conferences

GlobeNewsWire · 26 Aug 2026neutral

Candel Therapeutics announced it will present at September investor conferences. The company said the event will feature its clinical-stage multimodal immunotherapies, with participation from Paul Peter Tak, M.D.

Why it matters — A CADL watcher would care because conference presentations provide visibility into the company's clinical-stage immunotherapy pipeline and its leadership's engagement with investors.

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Seeking Alpha · 17 Aug 2026positive

Biotech stocks, especially small-caps, are seeing renewed optimism as macro and policy headwinds ease, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.

Why it matters — A CADL watcher would care because a broad improvement in sector sentiment and capital flows could translate into more favorable conditions for small-cap biotech names like Candel Therapeutics.

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

GlobeNewsWire · 13 Aug 2026neutral

Candel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing multimodal immunotherapies for cancer, announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The announcement was made on August 13, 2026.

Why it matters — CADL watchers would care because the quarterly financial results and corporate update offer the company's latest operational and financial status.

FAQ

Frequently asked questions about CADL stock

What is the CADL stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Candel Therapeutics, Inc. have a median 12-month price target of $23, with estimates ranging from $12 to $29. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CADL stock a buy right now?

Of the 9 analysts covering Candel Therapeutics, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Candel Therapeutics, Inc. 41 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CADL?

As at 12 Sept 2026, Candel Therapeutics, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (77 of 100).

Will CADL stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +113.4% from the last close, and Ticker Nerd's factor model ranks Candel Therapeutics, Inc. 41 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CADL stock forecast for 2030?

No analyst covering Candel Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CADL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $29 over the next 12 months.

How has CADL stock performed over the past year?

Candel Therapeutics, Inc. returned +114.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Candel Therapeutics, Inc. do?

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer.

What is the latest news on CADL?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors". Candel Therapeutics announced the appointment of Martine Zimmermann, PharmD, to its Board of Directors, effective September 8, 2026. The company is a clinical-stage biopharmaceutical firm developing immunotherapies for cancer patients.

Company

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer. Candel Therapeutics concentrates on off-the-shelf, multimodal biological therapies designed to stimulate anti-tumor immune responses and address solid tumors. Its current pipeline includes CAN-2409, an adenovirus-based program being evaluated in cancers such as prostate, non-small cell lung, and pancreatic cancer, as well as CAN-3110, a herpes simplex virus-based candidate for recurrent high-grade glioma. The company also develops the enLIGHTEN Discovery Platform, which is used to identify and advance new viral immunotherapy candidates. Headquartered in Needham, Massachusetts, Candel Therapeutics plays a specialized role in oncology by combining viral engineering with immunology to support the development of targeted cancer treatments.

CEO Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. · 55 employees · United States · https://www.candeltx.com